Elsevier

Clinical Therapeutics

Volume 18, Issue 3, May–June 1996, Pages 460-465
Clinical Therapeutics

The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension

https://doi.org/10.1016/S0149-2918(96)80026-9Get rights and content

Abstract

The effectiveness of dorzolamide 2%, a topical carbonic anhydrase inhibitor, administered three times daily (TID) concomitantly with timolol 0.5% given twice daily (BID) was evaluated in one arm of a large, 1-year, multicenter efficacy and safety trial. That study compared dorzolamide 2% TID with betaxolol 0.5% BID and timolol 0.5% BID as monotherapy in patients with open-angle glaucoma or ocular hypertension. Ninety-seven patients with uncontrolled intraocular pressure (IOP) (ie, greater than 21 mm Hg) or with a reduction with IOP of less than 15% from baseline during monotherapy with dorzolamide required 0.5% timolol BID as adjunctive therapy; 95 patients were evaluated for efficacy. IOP was measured 1 week after starting adjunctive therapy and at all subsequent study visits. Data were evaluated as change in IOP from original baseline and change in IOP from end of monotherapy treatment. A clinically meaningful additive effect on IOP was observed at all time points. After 1 week of adjunctive therapy, the mean percent reduction from baseline in peak and afternoon trough IOPs was 34% and 28%, respectively. These results demonstrate that dorzolamide and timolol have an additive effect in lowering IOP. This combination was generally well tolerated by the patients in this study.

References (10)

  • DG Vaughan et al.

    Glaucoma

  • MB Shields
  • LM Hurvitz et al.

    New development in the drug treatment of glaucoma

    Drugs

    (1991)
  • MF Sugrue et al.

    A study of the in vitro inhibition of carbonic anhydrase isoenzymes I, II and IV

    Invest Ophthalmol Visual Sci

    (1993)
  • EA Lippa et al.

    Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

    Arch Ophthalmol

    (1992)
There are more references available in the full text version of this article.

Cited by (31)

  • Carbonic anhydrase inhibitors

    2009, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas: Eighth Edition
  • Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors

    2000, Progress in Retinal and Eye Research
    Citation Excerpt :

    After 1 week of adjunctive therapy, the mean percentage change from the end of monotherapy with dorzolamide was 20% at peak and 16% at afternoon trough. The corresponding percentage reductions from baseline were 34 and 28% (Hartenbaum, 1996). The frequency of dosing with timolol has been reduced from twice daily to once daily by incorporating the drug in a gellan gum vehicle (Laurence et al., 1993), an anionic heteropolysaccharide that forms a clear gel in the presence of cations (Rozier et al., 1989).

View all citing articles on Scopus
View full text